Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1997 Jun;105(Suppl 4):763–766. doi: 10.1289/ehp.97105s4763

Acetylation as an indicator of risk.

N P Lang 1
PMCID: PMC1470040  PMID: 9255559

Abstract

Aromatic amine acetylation has been recognized for many years as an important metabolic polymorphism in humans because of its relationship to disease. This system serves as a model in risk assessment because of its role in drug and carcinogen activation and detoxification and because of the case with which it is measured. However, possible interactions of NAT1-NAT2 phenotypes or genotypes illustrate the complexity of xenobiotic metabolism pathways. Moreover, the use of such information for risk assessment is further complicated by the association of the rapid phenotype with increased risk in colon cancer and the slow phenotype with increased risk in urinary bladder cancer. Before this biomarker can be effectively utilized as a significant predictor of individual risk, it will be necessary to identify specific sources of aromatic amine exposure and to characterize further the substrate specificity of NAT1 and NAT2 in relation to the multiplicity of enzyme variants occurring in human populations.

Full text

PDF
763

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Badawi A. F., Hirvonen A., Bell D. A., Lang N. P., Kadlubar F. F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995 Nov 15;55(22):5230–5237. [PubMed] [Google Scholar]
  2. Bartsch H., Caporaso N., Coda M., Kadlubar F., Malaveille C., Skipper P., Talaska G., Tannenbaum S. R., Vineis P. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst. 1990 Dec 5;82(23):1826–1831. doi: 10.1093/jnci/82.23.1826. [DOI] [PubMed] [Google Scholar]
  3. Bell D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R. C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 1995 Aug 15;55(16):3537–3542. [PubMed] [Google Scholar]
  4. Bell D. A., Taylor J. A., Butler M. A., Stephens E. A., Wiest J., Brubaker L. H., Kadlubar F. F., Lucier G. W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993 Aug;14(8):1689–1692. doi: 10.1093/carcin/14.8.1689. [DOI] [PubMed] [Google Scholar]
  5. Burgess E. J., Trafford J. A. Acetylator phenotype in patients with lung carcinoma--a negative report. Eur J Respir Dis. 1985 Jul;67(1):17–19. [PubMed] [Google Scholar]
  6. Butler M. A., Lang N. P., Young J. F., Caporaso N. E., Vineis P., Hayes R. B., Teitel C. H., Massengill J. P., Lawsen M. F., Kadlubar F. F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992 Jun;2(3):116–127. doi: 10.1097/00008571-199206000-00003. [DOI] [PubMed] [Google Scholar]
  7. Cartwright R. A., Glashan R. W., Rogers H. J., Ahmad R. A., Barham-Hall D., Higgins E., Kahn M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982 Oct 16;2(8303):842–845. doi: 10.1016/s0140-6736(82)90810-8. [DOI] [PubMed] [Google Scholar]
  8. Cribb A. E., Grant D. M., Miller M. A., Spielberg S. P. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther. 1991 Dec;259(3):1241–1246. [PubMed] [Google Scholar]
  9. Cribb A. E., Isbrucker R., Levatte T., Tsui B., Gillespie C. T., Renton K. W. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics. 1994 Jun;4(3):166–170. [PubMed] [Google Scholar]
  10. Derewlany L. O., Knie B., Koren G. Human placental transfer and metabolism of p-aminobenzoic acid. J Pharmacol Exp Ther. 1994 May;269(2):761–765. [PubMed] [Google Scholar]
  11. Dewan A., Chattopadhyay P., Kulkarni P. K. N-acetyltransferase activity--a susceptibility factor in human bladder carcinogenesis. Indian J Cancer. 1995 Mar;32(1):15–19. [PubMed] [Google Scholar]
  12. Evans W. E., Relling M. V., Petros W. P., Meyer W. H., Mirro J., Jr, Crom W. R. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther. 1989 May;45(5):568–573. doi: 10.1038/clpt.1989.74. [DOI] [PubMed] [Google Scholar]
  13. Flammang T. J., Yamazoe Y., Guengerich F. P., Kadlubar F. F. The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype. Carcinogenesis. 1987 Dec;8(12):1967–1970. doi: 10.1093/carcin/8.12.1967. [DOI] [PubMed] [Google Scholar]
  14. Friesen M. D., Kaderlik K., Lin D., Garren L., Bartsch H., Lang N. P., Kadlubar F. F. Analysis of DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine in rat and human tissues by alkaline hydrolysis and gas chromatography/electron capture mass spectrometry: validation by comparison with 32P-postlabeling. Chem Res Toxicol. 1994 Nov-Dec;7(6):733–739. doi: 10.1021/tx00042a004. [DOI] [PubMed] [Google Scholar]
  15. Goel U. C., Bajaj S., Gupta O. P., Dwivedi N. C., Dubey A. L. Isoniazid induced neuropathy in slow versus rapid acetylators: an electrophysiological study. J Assoc Physicians India. 1992 Oct;40(10):671–672. [PubMed] [Google Scholar]
  16. Grant D. M., Tang B. K., Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther. 1983 Mar;33(3):355–359. doi: 10.1038/clpt.1983.45. [DOI] [PubMed] [Google Scholar]
  17. Grant D. M., Tang B. K., Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther. 1983 May;33(5):591–602. doi: 10.1038/clpt.1983.80. [DOI] [PubMed] [Google Scholar]
  18. Gutmann L., Martin J. D., Welton W. Dapsone motor neuropathy--an axonal disease. Neurology. 1976 Jun;26(6 Pt 1):514–516. doi: 10.1212/wnl.26.6.514. [DOI] [PubMed] [Google Scholar]
  19. Hanson A., Melander A., Wåhlin-Boll E. Acetylator phenotyping: a comparison of the isoniazid and dapsone tests. Eur J Clin Pharmacol. 1981;20(3):233–234. doi: 10.1007/BF00544604. [DOI] [PubMed] [Google Scholar]
  20. Hein D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J., Grant D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993 Aug;14(8):1633–1638. doi: 10.1093/carcin/14.8.1633. [DOI] [PubMed] [Google Scholar]
  21. Hickman D., Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol. 1991 Aug 8;42(5):1007–1014. doi: 10.1016/0006-2952(91)90282-a. [DOI] [PubMed] [Google Scholar]
  22. Hirvonen A., Nylund L., Kociba P., Husgafvel-Pursiainen K., Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis. 1994 May;15(5):813–815. doi: 10.1093/carcin/15.5.813. [DOI] [PubMed] [Google Scholar]
  23. Ilett K. F., David B. M., Detchon P., Castleden W. M., Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 1987 Mar 1;47(5):1466–1469. [PubMed] [Google Scholar]
  24. Ilett K. F., Ingram D. M., Carpenter D. S., Teitel C. H., Lang N. P., Kadlubar F. F., Minchin R. F. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol. 1994 Mar 2;47(5):914–917. doi: 10.1016/0006-2952(94)90493-6. [DOI] [PubMed] [Google Scholar]
  25. Kadlubar F. F. Carcinogenic aromatic amine metabolism and DNA adduct detection in humans. Princess Takamatsu Symp. 1990;21:329–338. [PubMed] [Google Scholar]
  26. Kalow W. Ethnic differences in reactions to drugs and xenobiotics. Caffeine and other drugs. Prog Clin Biol Res. 1986;214:331–341. [PubMed] [Google Scholar]
  27. Lang N. P., Butler M. A., Massengill J., Lawson M., Stotts R. C., Hauer-Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):675–682. [PubMed] [Google Scholar]
  28. Lang N. P., Chu D. Z., Hunter C. F., Kendall D. C., Flammang T. J., Kadlubar F. F. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg. 1986 Nov;121(11):1259–1261. doi: 10.1001/archsurg.121.11.1259. [DOI] [PubMed] [Google Scholar]
  29. Lin H. J., Han C. Y., Lin B. K., Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994 Jun;4(3):125–134. doi: 10.1097/00008571-199406000-00003. [DOI] [PubMed] [Google Scholar]
  30. Mashimo M., Suzuki T., Abe M., Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet. 1992 Sep-Oct;90(1-2):139–143. doi: 10.1007/BF00210758. [DOI] [PubMed] [Google Scholar]
  31. Mitchell J. R., Thorgeirsson U. P., Black M., Timbrell J. A., Snodgrass W. R., Potter W. Z., Jollow H. R., Keiser H. R. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther. 1975 Jul;18(1):70–79. doi: 10.1002/cpt197518170. [DOI] [PubMed] [Google Scholar]
  32. Mommsen S., Aagaard J. Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett. 1986 Aug;32(2):199–205. doi: 10.1016/0304-3835(86)90120-5. [DOI] [PubMed] [Google Scholar]
  33. Ohsako S., Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem. 1990 Mar 15;265(8):4630–4634. [PubMed] [Google Scholar]
  34. Turesky R. J., Lang N. P., Butler M. A., Teitel C. H., Kadlubar F. F. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 1991 Oct;12(10):1839–1845. doi: 10.1093/carcin/12.10.1839. [DOI] [PubMed] [Google Scholar]
  35. Vatsis K. P., Weber W. W. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys. 1993 Feb 15;301(1):71–76. doi: 10.1006/abbi.1993.1116. [DOI] [PubMed] [Google Scholar]
  36. Vineis P., Bartsch H., Caporaso N., Harrington A. M., Kadlubar F. F., Landi M. T., Malaveille C., Shields P. G., Skipper P., Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 1994 May 12;369(6476):154–156. doi: 10.1038/369154a0. [DOI] [PubMed] [Google Scholar]
  37. Vineis P., Schulte P. A. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J Clin Epidemiol. 1995 Feb;48(2):189–197. doi: 10.1016/0895-4356(94)00131-9. [DOI] [PubMed] [Google Scholar]
  38. Weber W. W., Cohen S. N. The mechanism of isoniazid acetylation by human N-acetyltransferase. Biochim Biophys Acta. 1968 Jan 8;151(1):276–278. doi: 10.1016/0005-2744(68)90184-8. [DOI] [PubMed] [Google Scholar]
  39. Weber W. W., Hein D. W. N-acetylation pharmacogenetics. Pharmacol Rev. 1985 Mar;37(1):25–79. [PubMed] [Google Scholar]
  40. Weber W. W., Vatsis K. P. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 1993 Aug;3(4):209–212. doi: 10.1097/00008571-199308000-00006. [DOI] [PubMed] [Google Scholar]
  41. Wolf H., Lower G. M., Jr, Bryan G. T. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol. 1980;14(2):161–165. doi: 10.3109/00365598009179555. [DOI] [PubMed] [Google Scholar]
  42. Wong P., Leyland-Jones B., Wainer I. W. A competitive enzyme linked immunosorbent assay for the determination of N-acetyltransferase (NAT2) phenotypes. J Pharm Biomed Anal. 1995 Aug;13(9):1079–1086. doi: 10.1016/0731-7085(95)01550-5. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES